CXCL10/XCL1 fusokine elicits in vitro and in vivo chemotaxis
- 393 Downloads
Fusokines are proteins formed by the fusion of two cytokines. They have greater bioavailability and therapeutic potential than individual cytokines or a combination of different cytokines. Interferon-gamma-inducible protein 10 (CXCL10) and lymphotactin (XCL1) are members of the chemotactic family of cytokines, which induce tumor regression by eliciting immune-system cell chemotaxis. We engineered a replication-deficient adenoviral system expressing CXCL10/XCL1 fusokine (Ad FIL) and assessed its chemotactic response in vitro and in vivo. The CXCL10/XCL1 fusokine elicited a greater chemotactic effect in IL-2 stimulated lymphocytes than individual or combined cytokines in vitro. CXCL10/XCL1 fusokine biological activity was demonstrated in vivo by intratumoral chemoattraction of CXCR3+ cells. Thus, this novel CXCL10/XCL1 fusokine may represent a potential tool for gene therapy treatment of cancer and other illnesses that require triggering immune-system cell recruitment.
KeywordsAdenovirus Cancer therapy CXCL10 Fusokine Gene therapy Immunotherapy Interferon-gamma-inducible protein 10 Lymphotactin
This work was supported by Programa de Apoyo a la Investigación en Ciencia y Tecnología (PAICYT) No. SA381-10 from the UANL, and by ConsejoNacional de Ciencia y Tecnología (CONACYT) Grant No. CB-10-158509. YESL and JJPT were recipients of scholarships from CONACYT.
Conflict of interest
The authors declare that they have no conflict of interest.
- Cairns CM, Gordon JR, Li F et al (2001) Lymphotactin expression by engineered myeloma cells drives tumor regression: mediation by CD4+ and CD8+ T cells and neutrophils expressing XCR1 receptor. J Immunol Baltim Md 1950 167:57–65Google Scholar
- Russell HV, Strother D, Mei Z et al (2007) Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother Hagerstown Md 1997 30:227–233Google Scholar
- Wang P, Yang X, Xu W et al (2010) Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: a strategy for chemokine-based multi-target-directed cancer therapy. Cancer Immunol Immunother CII 59:1715–1726CrossRefGoogle Scholar